The PRISMAP Radiolanthanides Workshop

Contribution List

15. 161Tb a promising radionuclide for early TRT: absorbed doses compared to 177Lu in micrometastases, cell clusters, and single tumour cells

Dr Elif Hindié ((CHU-Bordeaux)

21. 161Tb therapies for clinical trials-experiences

David Schmid (PSI)

23. A regulator perspective on clinical trials using new radionuclides

Dr Anna C. Senn (FOPH)

6. Advancing Auger electron therapy: Developing methods for high-resolution spectral characterization of radioisotopes

Emilio Andrea Maugeri (PSI - Paul Scherrer Institut)

13. CERN-MEDICIS: Experience of mass-separation with radiolanthanides towards their clinical translation

Dr Thierry Stora (CERN)

3. Cross-section measurements towards an optimized production of theranostic radionuclides at the Bern Medical Cyclotron

Saverio Braccini (University of Bern)

5. Decay data: the importance and impact of metrology

Dr Sean Collins (NPL)

17. Development of 161Tb and 153Sm based radiopharmaceuticals

Dr Maarten Ooms (SCK-CEN)

16. Dose-response effects of the additional Auger and IC electrons of 161Tb-vs 177Lu-labelled agonists and antagonists

Dr Michel Koole (KU Leuven)

14. Dosimetric comparison of the radiolanthanides 177Lu and 161Tb for cancer therapies with radiopharmaceuticals

Dr Peter Bernhardt (Gothenburg University)

12. High-purity radionuclides at ISOL@MYRRHA

Dr Lucia Popescu (SEK-CEN)

20. Hybrid hydroxypyridinone-macrocyclic chelators for coordination of lanthanide and actinide radionuclides

Michelle Ma (School of Biomedical Engineering and Imaging Sciences, King's College London)

11. Impact-TATTOOS-Novel radionuclides production in Switzerland: A design status report

Robert Eichler (PSI - Paul Scherrer Institut)

10. Mass separation of stable and radioactive lanthanide isotopes

Dr Ulli Köster (ILL)

4. Nuclear data measurement of lanthanides

Frédéric J Juget (IRA)

24. Preclinical Development of 161Tb-based Radiopharmaceuticals for Radioligand Therapy

Dr Cristina Müller (PSI)

18. Preclinical studies of subcellular targeted 161Tb-complexes for cancer radiotheranostics

Dr Antonio Rocha Paulo (IST-ID)

1. Production and application of radiolanthanides at TRIUMF

Paul Schaffer (TRIUMF)

8. Production and radiochemical processing of medical radiolanthanides

Dr Michiel Van de Voorde (SCK-CEN)

9. Production of novel medically relevant radiolanthanides at Paul Scherrer Institute

Zeynep Talip (PSI - Paul Scherrer Institut)

19. Production of Radiolanthanides for medical applications in the USA

Paul Ellison (University of Wisconsin Madison)

22. Radiolanthanides in the pharmaceutical regulatory framework in Europe

Dr Clemens Decristoforo (MUI)

2. Studies of different production paths of 155Tb on Gd targets: from target manufacturing to Tb/Gd separation

Dr Thomas Sounalet (Arronax)

7. Tb radionuclides for imaging and therapy: How far have we progressed?

Nicholas Philip van der Meulen (PSI - Paul Scherrer Institut)